Pharmacokinetics in children
No information
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Improving asthma control in severe persistent asthma |
|
|
| Chronic urticaria |
- Subcutaneous
-
6 years
up to
12 years
There are only a few case descriptions available about the use of omalizumab in chronic urticaria in children. Properly substantiated dose recommendations can therefore not be given. A description of the cases therefore follows:
- 300 mg every 2 weeks: 10-year-old girl [Netchiporouk 2015]
- 300 mg every 4 weeks: 8-year-old boy [Viswanathan 2013]
- 150 mg every 2 weeks: 10-year-old boy [Uysal 2014]
- 150 mg every 4 weeks: 7 and 10-year-old [Sussman 2014], 4 and 5-year-old girls [Netchiporouk 2015]
When the urticaria goes into remission, the dose is reduced. Treatment by a paediatric allergologist or pediatric dermatologist who has experience with using omalizumab for this indication.
-
12 years
up to
18 years
|
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
< 12 years:
Very common (> 10%): , fever.
Common (1-10%): headaches; epigastric distress.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Leukotriene receptor antagonists |
|
|
|
R03DC03
|
| Other systemic drugs for obstructive airway diseases |
|
|
|
R03DX09
|
|
|
|
R03DX11
|
References
-
Novartis Europharm Limited., SPC Xolair( EU/1/05/319/002-4) 14-4-2015, www.geneesmiddeleninformatiebank.nl
-
Sussman G et al. , Real-life experiences with omalizumab for the treatment of chronic urticarial. , Ann Allergy Asthma Immunol., 2014, Feb;112(2):, 170-4
-
Uysal P et al. J , An algorithm for treating chronic urticaria with omalizumab: dose interval should be individualized. , Allergy Clin Immunol., 2014, Mar;133(3):, 914-5.e2
-
Viswanathan RK et al. 2013, Retrospective analysis of the efficacy of omalizumab in chronic refractory urticarial., Allergy Asthma Proc., 2013, Sep-Oct;34(5):, 446-52
-
Netchiporouk E et al., Management of pediatric chronic spontaneous and physical urticaria patients with omalizumab: case series., Pediatr Allergy Immunol., 2015, Sep;26(6), 585-8
-
Sussman G et al., Real-life experiences with omalizumab for the treatment of chronic urticarial., Ann Allergy Asthma Immunol., 2014, Feb;112(2):, 170-4
-
Uysal P et al. J, An algorithm for treating chronic urticaria with omalizumab: dose interval should be individualized., Allergy Clin Immunol., 2014, Mar;133(3):, 914-5.e2
Therapeutic Drug Monitoring
Overdose